ReviewJournal of gastric cancer2019
Clinical Implementation of Precision Medicine in Gastric Cancer.
Review in Journal of gastric cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Preoperative electrolyte-based metabolic biomarkers for prognostic assessment in gastric cancer: a multicenter study.Frontiers in endocrinology · 2026Article
- Article
- Spatially resolved endothelial signaling via nampt-itga5 drives immune evasion in stem-like gastric cancer.Cancer immunology, immunotherapy : CII · 2025Article
- PKA-Mediated Phosphorylation of SFRP4 Promotes Wnt/β-Catenin Activation and Cancer Stemness in Gastric Cancer.International journal of molecular sciences · 2025Article
- Proteome-based molecular subtyping and therapeutic target prediction in gastric cancer.Molecular oncology · 2024Article
- Genomic and evolutionary characteristics of metastatic gastric cancer by routes.British journal of cancer · 2023Article
- Updated Epidemiology of Gastric Cancer in Asia: Decreased Incidence but Still a Big Challenge.Cancers · 2023Review
- The role of senescence genes in the treatment, prognosis, and tumor microenvironment of gastric cancer.American journal of translational research · 2023Article
- EBV and MSI Status in Gastric Cancer: Does It Matter?Cancers · 2022Article
- Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies.Journal of Korean medical science · 2022Article
- Copy number alterations and epithelial‑mesenchymal transition genes in diffuse and intestinal gastric cancers in Mexican patients.Molecular medicine reports · 2022Article
- Yes-associated protein gene overexpression regulated by β-catenin promotes gastric cancer cell tumorigenesis.Technology and health care : official journal of the European Society for Engineering and Medicine · 2022Article
- Differences in Somatic Mutation Profiles between Korean Gastric Cancer and Gastric Adenoma Patients.Journal of clinical medicine · 2021Article
- Development and Application of Patient-Derived Cancer Organoidsin Clinical Management of Gastrointestinal Cancer: A State-of-the-Art Review.Frontiers in oncology · 2021Review
- Molecular target: pan-AKT in gastric cancer.ESMO open · 2020Review
- Identification and Validation of an Individualized EMT-Related Prognostic Risk Score Formula in Gastric Adenocarcinoma Patients.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the deadliest malignancies in the world. Currently, clinical treatment decisions are mostly made based on the extent of the tumor and its anatomy, such as tumor-node-metastasis staging. Recent advances in genome-wide molecular technology have enabled delineation of the molecular characteristics of GC. Based on this, efforts have been made to classify GC into molecular subtypes with distinct prognosis and therapeutic response. Simplified algorithms based on protein and RNA expressions have been proposed to reproduce the GC classification in the clinical field. Furthermore, a recent study established a single patient classifier (SPC) predicting the prognosis and chemotherapy response of resectable GC patients based on a 4-gene real-time polymerase chain reaction assay. GC patient stratification according to SPC will enable personalized therapeutic strategies in adjuvant settings. At the same time, patient-derived xenografts and patient-derived organoids are now emerging as novel preclinical models for the treatment of GC. These models recapitulate the complex features of the primary tumor, which is expected to facilitate both drug development and clinical therapeutic decision making. An integrated approach applying molecular patient stratification and patient-derived models in the clinical realm is considered a turning point in precision medicine in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.